vs
Apellis Pharmaceuticals, Inc.（APLS）与ICHOR HOLDINGS, LTD.（ICHR）财务数据对比。点击上方公司名可切换其他公司
ICHOR HOLDINGS, LTD.的季度营收约是Apellis Pharmaceuticals, Inc.的1.1倍（$223.6M vs $199.9M），ICHOR HOLDINGS, LTD.净利率更高（-7.1% vs -29.5%，领先22.4%），ICHOR HOLDINGS, LTD.同比增速更快（-4.2% vs -5.9%），ICHOR HOLDINGS, LTD.自由现金流更多（$5.9M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 5.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Ichor Holdings Ltd.是面向全球半导体制造领域的关键流体输送系统、子系统及相关组件的设计、制造供应商，产品集成于晶圆前端加工设备，为北美、东亚、欧洲的领先半导体设备与芯片厂商提供先进逻辑、存储芯片生产配套支持。
APLS vs ICHR — 直观对比
营收规模更大
ICHR
是对方的1.1倍
$199.9M
营收增速更快
ICHR
高出1.8%
-5.9%
净利率更高
ICHR
高出22.4%
-29.5%
自由现金流更多
ICHR
多$20.2M
$-14.3M
两年增速更快
APLS
近两年复合增速
5.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $223.6M |
| 净利润 | $-59.0M | $-16.0M |
| 毛利率 | — | 9.4% |
| 营业利润率 | -25.6% | -6.2% |
| 净利率 | -29.5% | -7.1% |
| 营收同比 | -5.9% | -4.2% |
| 净利润同比 | -62.2% | -304.8% |
| 每股收益（稀释后） | $-0.40 | $-0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSICHR
| Q4 25 | $199.9M | $223.6M | ||
| Q3 25 | $458.6M | $239.3M | ||
| Q2 25 | $178.5M | $240.3M | ||
| Q1 25 | $166.8M | $244.5M | ||
| Q4 24 | $212.5M | $233.3M | ||
| Q3 24 | $196.8M | $211.1M | ||
| Q2 24 | $199.7M | $203.2M | ||
| Q1 24 | $172.3M | $201.4M |
净利润APLSICHR
| Q4 25 | $-59.0M | $-16.0M | ||
| Q3 25 | $215.7M | $-22.9M | ||
| Q2 25 | $-42.2M | $-9.4M | ||
| Q1 25 | $-92.2M | $-4.6M | ||
| Q4 24 | $-36.4M | $-3.9M | ||
| Q3 24 | $-57.4M | $-2.8M | ||
| Q2 24 | $-37.7M | $-5.1M | ||
| Q1 24 | $-66.4M | $-9.0M |
毛利率APLSICHR
| Q4 25 | — | 9.4% | ||
| Q3 25 | — | 4.6% | ||
| Q2 25 | — | 11.3% | ||
| Q1 25 | — | 11.7% | ||
| Q4 24 | — | 11.6% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 12.6% | ||
| Q1 24 | — | 11.4% |
营业利润率APLSICHR
| Q4 25 | -25.6% | -6.2% | ||
| Q3 25 | 48.7% | -8.1% | ||
| Q2 25 | -18.6% | -2.0% | ||
| Q1 25 | -50.0% | -0.5% | ||
| Q4 24 | -12.3% | -0.5% | ||
| Q3 24 | -24.0% | -0.2% | ||
| Q2 24 | -14.7% | -1.1% | ||
| Q1 24 | -36.0% | -1.9% |
净利率APLSICHR
| Q4 25 | -29.5% | -7.1% | ||
| Q3 25 | 47.0% | -9.6% | ||
| Q2 25 | -23.6% | -3.9% | ||
| Q1 25 | -55.3% | -1.9% | ||
| Q4 24 | -17.1% | -1.7% | ||
| Q3 24 | -29.2% | -1.3% | ||
| Q2 24 | -18.9% | -2.5% | ||
| Q1 24 | -38.5% | -4.5% |
每股收益（稀释后）APLSICHR
| Q4 25 | $-0.40 | $-0.46 | ||
| Q3 25 | $1.67 | $-0.67 | ||
| Q2 25 | $-0.33 | $-0.28 | ||
| Q1 25 | $-0.74 | $-0.13 | ||
| Q4 24 | $-0.30 | $-0.11 | ||
| Q3 24 | $-0.46 | $-0.08 | ||
| Q2 24 | $-0.30 | $-0.15 | ||
| Q1 24 | $-0.54 | $-0.30 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $98.3M |
| 总债务越低越好 | — | $123.5M |
| 股东权益账面价值 | $370.1M | $663.9M |
| 总资产 | $1.1B | $942.9M |
| 负债/权益比越低杠杆越低 | — | 0.19× |
8季度趋势，按日历期对齐
现金及短期投资APLSICHR
| Q4 25 | $466.2M | $98.3M | ||
| Q3 25 | $479.2M | $92.5M | ||
| Q2 25 | $370.0M | $92.2M | ||
| Q1 25 | $358.4M | $109.3M | ||
| Q4 24 | $411.3M | $108.7M | ||
| Q3 24 | $396.9M | $116.4M | ||
| Q2 24 | $360.1M | $114.3M | ||
| Q1 24 | $325.9M | $102.1M |
总债务APLSICHR
| Q4 25 | — | $123.5M | ||
| Q3 25 | — | $123.5M | ||
| Q2 25 | — | $125.0M | ||
| Q1 25 | — | $126.8M | ||
| Q4 24 | — | $128.5M | ||
| Q3 24 | — | $130.3M | ||
| Q2 24 | — | $130.2M | ||
| Q1 24 | $93.1M | $131.9M |
股东权益APLSICHR
| Q4 25 | $370.1M | $663.9M | ||
| Q3 25 | $401.2M | $676.2M | ||
| Q2 25 | $156.3M | $694.1M | ||
| Q1 25 | $164.2M | $700.4M | ||
| Q4 24 | $228.5M | $698.3M | ||
| Q3 24 | $237.1M | $697.3M | ||
| Q2 24 | $264.3M | $694.9M | ||
| Q1 24 | $266.7M | $697.2M |
总资产APLSICHR
| Q4 25 | $1.1B | $942.9M | ||
| Q3 25 | $1.1B | $966.6M | ||
| Q2 25 | $821.4M | $985.1M | ||
| Q1 25 | $807.3M | $1.0B | ||
| Q4 24 | $885.1M | $995.6M | ||
| Q3 24 | $901.9M | $975.9M | ||
| Q2 24 | $904.5M | $947.7M | ||
| Q1 24 | $831.9M | $957.4M |
负债/权益比APLSICHR
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.19× | ||
| Q2 24 | — | 0.19× | ||
| Q1 24 | 0.35× | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $9.2M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $5.9M |
| 自由现金流率自由现金流/营收 | -7.1% | 2.6% |
| 资本支出强度资本支出/营收 | 0.1% | 1.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-6.3M |
8季度趋势，按日历期对齐
经营现金流APLSICHR
| Q4 25 | $-14.2M | $9.2M | ||
| Q3 25 | $108.5M | $9.2M | ||
| Q2 25 | $4.4M | $-7.5M | ||
| Q1 25 | $-53.4M | $19.0M | ||
| Q4 24 | $19.4M | $-2.5M | ||
| Q3 24 | $34.1M | $8.1M | ||
| Q2 24 | $-8.3M | $17.5M | ||
| Q1 24 | $-133.0M | $4.8M |
自由现金流APLSICHR
| Q4 25 | $-14.3M | $5.9M | ||
| Q3 25 | $108.3M | $2.1M | ||
| Q2 25 | $4.4M | $-14.8M | ||
| Q1 25 | $-53.4M | $496.0K | ||
| Q4 24 | $19.3M | $-6.9M | ||
| Q3 24 | — | $2.2M | ||
| Q2 24 | $-8.4M | $14.6M | ||
| Q1 24 | $-133.3M | $314.0K |
自由现金流率APLSICHR
| Q4 25 | -7.1% | 2.6% | ||
| Q3 25 | 23.6% | 0.9% | ||
| Q2 25 | 2.5% | -6.2% | ||
| Q1 25 | -32.0% | 0.2% | ||
| Q4 24 | 9.1% | -3.0% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | -4.2% | 7.2% | ||
| Q1 24 | -77.3% | 0.2% |
资本支出强度APLSICHR
| Q4 25 | 0.1% | 1.5% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.0% | 7.6% | ||
| Q4 24 | 0.0% | 1.9% | ||
| Q3 24 | 0.0% | 2.8% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.2% | 2.2% |
现金转化率APLSICHR
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
ICHR
| Other | $101.6M | 45% |
| US | $67.4M | 30% |
| Other Countries | $29.7M | 13% |
| Europe | $24.9M | 11% |
